{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:56:10Z","timestamp":1791327370142,"version":"4.3.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.jtho.2016.06.024","type":"journal-article","created":{"date-parts":[[2016,7,21]],"date-time":"2016-07-21T13:22:24Z","timestamp":1469107344000},"page":"2018-2021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207"],"prefix":"10.1016","volume":"11","author":[{"given":"Paul","family":"Wheatley-Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quincy","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Seely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenwood","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Maksymiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope A.","family":"Bradbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.06.024_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/bjc.2012.245","article-title":"Prognosis and prognostic factors of patients with mesothelioma: a population-based study","volume":"107","author":"van der Bij","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.06.024_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.06.024_bib3","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.06.024_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-10-1451","article-title":"Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies","volume":"71","author":"Hu-Lowe","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2016.06.024_bib5","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1158\/1078-0432.CCR-15-1622","article-title":"A\u00a0phase I study of the anti-activin receptor-like kinase 1 (ALK-1) monoclonal antibody PF-03446962 in patients with advanced solid tumors","volume":"22","author":"Goff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2016.06.024_bib6","doi-asserted-by":"crossref","first-page":"e26218","DOI":"10.4161\/onci.26218","article-title":"Immunological effects of the TGFbeta-blocking antibody GC1008 in malignant pleural mesothelioma patients","volume":"2","author":"Stevenson","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jtho.2016.06.024_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2016.06.024_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s004280050388","article-title":"Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma","volume":"435","author":"Konig","year":"1999","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jtho.2016.06.024_bib9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.lungcan.2015.06.018","article-title":"Second line therapy in malignant pleural mesothelioma: A systematic review","volume":"89","author":"Buikhuisen","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.06.024_bib10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.06.024_bib11","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/iju.12084","article-title":"Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis","volume":"20","author":"Karashima","year":"2013","journal-title":"Int J Urol"},{"key":"10.1016\/j.jtho.2016.06.024_bib12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1684\/ecn.2009.0175","article-title":"Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist","volume":"20","author":"Alessi","year":"2009","journal-title":"Eur Cytokine Netw"},{"key":"10.1016\/j.jtho.2016.06.024_bib13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.cell.2007.08.038","article-title":"Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels","volume":"131","author":"Fischer","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jtho.2016.06.024_bib14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2009-08-237412","article-title":"Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy","volume":"115","author":"Priceman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtho.2016.06.024_bib15","first-page":"2787","article-title":"Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells","volume":"31","author":"Arao","year":"2011","journal-title":"Anticancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416306062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086416306062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T06:10:28Z","timestamp":1600927828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416306062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1556086416306062"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.024","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma. CCTG Trial IND.207","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}